OTCMKTS:NRXGQ NephroGenex (NRXGQ) Stock Price, News & Analysis → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free NRXGQ Stock Alerts $0.0028 +0.00 (+∞) (As of 05/24/2017) Add Compare Share Share Today's Range$0.0028▼$0.002850-Day Range N/A52-Week Range$0.00▼$0.21Volume2,000 shsAverage Volume26,223 shsMarket Capitalization$36,260.00P/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get NephroGenex alerts: Email Address Ad Weiss RatingsThe ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …Click here to see the presentation now. About NephroGenex Stock (OTCMKTS:NRXGQ)NephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.Read More NRXGQ Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NRXGQ Stock News HeadlinesAugust 24, 2023 | investing.comElicera Therapeutics AB (ELIC)August 17, 2023 | investing.comLL Lucky Games publ AB (LADYLU)May 13, 2024 | Porter & Company (Ad)Obama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.July 13, 2023 | investing.comXinjiang Daqo New Energy Co Ltd (688303)July 12, 2023 | investing.comTsukuba Bank Ltd (8338)July 11, 2023 | investing.comPEXA Group Ltd (PXA)June 21, 2023 | investing.comKosei Securities Co Ltd (8617)May 19, 2023 | investing.comNusatama Berkah Tbk PT (NTBK)May 13, 2024 | Porter & Company (Ad)Obama’s Forever Term [exposed]America’s Last Election New documentary, America’s Last Election, reveals the true (and terrifying) story of how the D.C. establishment has engineered a brutal new crisis that could hand them permanent power. Power they will use to reshape America to their dark, dystopian vision.May 19, 2023 | investing.comOlympic Group Corp (8289)May 18, 2023 | investing.comShandong Sanyuan Biotechnology Co Ltd (301206)May 18, 2023 | investing.comOkinawa financial Group Inc (7350)May 18, 2023 | investing.comSelvas Healthcare Inc (208370)May 16, 2023 | investing.comAl-Bad Massuot Yitzhak Ltd (ALBA)May 16, 2023 | investing.comSeven Utilities and Power PCL (7UP)May 16, 2023 | investing.comYong Pyong Resort Corp (070960)May 16, 2023 | investing.comAksa Enerji Uretim AS (AKSEN)May 16, 2023 | investing.comMHP Hotel AG (CDZ0)March 30, 2023 | marketwatch.comRenal Disease Market | Insights and Opportunities for 2023-2030See More Headlines Receive NRXGQ Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NephroGenex and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorManufacturing Industry Electronic Computer Manufacturing Sub-IndustryN/A Current SymbolOTCMKTS:NRXGQ Previous SymbolNASDAQ:NRX CUSIPN/A CIK1338095 Webwww.nephrogenex.com Phone+1-609-5538887FaxN/AEmployees147,000Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding Shares12,950,000Free FloatN/AMarket Cap$36,260.00 OptionableNot Optionable BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesJohn P. Hamill CPAChief Executive Officer, Chief Financial OfficerKey CompetitorsZuoan FashionOTCMKTS:ZAHLYDex MediaOTCMKTS:DXMMQ(BVII)OTCMKTS:BVII(CBNR)OTCMKTS:CBNR(DGTC)OTCMKTS:DGTCView All Competitors NRXGQ Stock Analysis - Frequently Asked Questions How have NRXGQ shares performed in 2024? NephroGenex's stock was trading at $0.0028 on January 1st, 2024. Since then, NRXGQ shares have increased by 0.0% and is now trading at $0.0028. View the best growth stocks for 2024 here. How do I buy shares of NephroGenex? Shares of NRXGQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (OTCMKTS:NRXGQ) was last updated on 5/13/2024 by MarketBeat.com Staff From Our PartnersBill Clinton Backing Biden Replacement???The Freeport SocietyThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithThe Crypto 9-5 Escape PlanCrypto 101 MediaThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldGold Set to EXPLODE!Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NephroGenex, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.